Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

A biotech company is attempting to persuade Kansas legislators to modify the state’s controlled substances act in advance of ...

A recent drug discovery could eventually help the visually impaired and those suffering from multiple sclerosis, traumatic stroke, and Alzheimer’s disease regain some of their vision and mental ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...

Intelligent Omics' Dr Rob Grundy discusses how combining AI with big data can lead to better drug discovery processes and that partnerships can help more organisations leverage cutting-edge tools.

Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...